Company Overview - Auna S.A. (AUNA) is a notable stock within the Medical group, which consists of 1012 companies and is currently ranked 4 in the Zacks Sector Rank [2] - AUNA has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Comparison - Year-to-date, AUNA has achieved a return of approximately 25.8%, significantly outperforming the Medical sector's average return of 6.9% [4] - In comparison, another Medical stock, BioMarin Pharmaceutical (BMRN), has returned 8.3% year-to-date, highlighting AUNA's superior performance [4] Industry Context - Auna S.A. operates within the Medical Services industry, which includes 59 stocks and is currently ranked 83 in the Zacks Industry Rank; this industry has seen an average gain of 4.1% this year [5] - BioMarin Pharmaceutical belongs to the Medical - Biomedical and Genetics industry, which has 510 stocks and is ranked 70, with a year-to-date increase of 7.1% [6]

Core Viewpoint - Auna S.A. (AUNA) has shown a significant price increase of 18.5% over the past four weeks, with analysts projecting a mean price target of $12.15, indicating a potential upside of 39.3% from the current price of $8.72 [1] Price Target Analysis - The average price target consists of four estimates ranging from a low of $11 to a high of $13, with a standard deviation of $0.87, suggesting a relatively high agreement among analysts [2] - The lowest estimate indicates a potential increase of 26.2%, while the highest suggests a 49.1% upside [2] - A low standard deviation indicates a strong consensus among analysts regarding the stock's price movement direction [7] Earnings Estimates and Analyst Sentiment - Analysts have recently revised their earnings estimates for AUNA upward, which is a positive indicator for potential stock price increases [4][9] - The Zacks Consensus Estimate for the current year has increased by 7.5% due to one upward revision and no negative revisions in the last 30 days [10] - AUNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, further supporting its potential upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Company Performance - Auna S.A. has returned 27.1% year-to-date, significantly outperforming the average gain of 5.4% for Medical stocks [4] - The Zacks Consensus Estimate for Auna S.A.'s full-year earnings has increased by 3.3% over the past quarter, indicating improved analyst sentiment and earnings outlook [3] Industry Context - Auna S.A. is part of the Medical Services industry, which consists of 59 individual stocks and currently ranks 139 in the Zacks Industry Rank. This industry has gained an average of 4.3% year-to-date, showing that Auna S.A. is performing better than its peers in this sector [5] - Another notable stock in the Medical sector is BioNTech SE Sponsored ADR, which has returned 7.8% year-to-date and belongs to the Medical - Biomedical and Genetics industry, currently ranked 62 with a year-to-date gain of 13.5% [4][6]

Analyst Background - The analyst is a Latin American economist with over 10 years of experience in investment management and company analysis, specializing in finding discounted stocks [4] - The analyst has worked as a Portfolio Manager at a large financial institution and previously in investment banking and economic journalism, with experience mainly in tech, retail, and banking [2] - The analyst holds an Economic BS and an MBA, and focuses on bottom-up analysis as well as macro-driven situations [2] Investment Approach - The analyst is a fundamentalist investor searching for discounted stocks across Latin America and worldwide [2] - The analyst believes there is still room for finding Alpha in many stocks and taking advantage of market overreactions [4] Disclosure - The analyst has a beneficial long position in the shares of AUNA through stock ownership, options, or other derivatives [3] - The analyst wrote the article themselves and expresses their own opinions, without receiving compensation other than from Seeking Alpha [3] - The analyst has no business relationship with any company whose stock is mentioned in the article [3]

Exhibit 99.2 Condensed Consolidated Interim Financial Statements September 30, 2024 Auna S.A. and Subsidiaries Condensed Consolidated Interim Financial Statements September 30, 2024 | Contents | Page | | --- | --- | | Condensed Consolidated Interim Statement of Financial Position | 1 | | Condensed Consolidated Interim Statement of Income and Other | | | Comprehensive Income (Loss) | 2 | | Condensed Consolidated Interim Statement of Changes in Equity | 3 | | Condensed Consolidated Interim Statement of Cash F ...

Exhibit 99.2 Auna S.A. and Subsidiaries Condensed Consolidated Interim Financial Statements June 30, 2024 Auna S.A. and Subsidiaries Condensed Consolidated Interim Financial Statements June 30, 2024 | Contents | Page | | --- | --- | | Condensed Consolidated Interim Statement of Financial Position | 1 | | Condensed Consolidated Interim Statement of Income and Other | | | Comprehensive Income (Loss) | 2 | | Condensed Consolidated Interim Statement of Changes in Equity | 3 | | Condensed Consolidated Interim St ...

Exhibit 99.1 Auna Announces 1Q24 Financial Results Revenue increases 20% YoY to S/1,076 million, with operating profit increasing 26% to S/182 million Adjusted EBITDA margin of 20.4% in Peruvian operations Luxembourg, May 22, 2024 – Auna (NYSE: AUNA) ("Auna" or the "Company"), one of the largest and most recognized company in Latin America's healthcare industry with operations in Mexico, Colombia and Peru, today announced unaudited financial results for the three months ended March 31, 2024 ("first quarter ...